Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Indigo Diabetes

Explore full profile

Develops invisible sensors for people living with diabetes

Ghent, BelgiumFounded 2016Health Tech & Medtech
Valuation $100–500M Latest valuation · 2020
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Indigo Diabetes and the history behind them.

About Indigo Diabetes

Indigo Diabetes N.V. is a Belgian medical device company developing a continuous multi-metabolite monitoring (CMM) system for people with chronic diseases, with an initial focus on diabetes. Founded in 2016 by Dr. Danaë Delbeke and her team as a spin-off from Ghent University and imec, a leading research center in nanoelectronics, the company is headquartered in Ghent, Belgium, with a US subsidiary, Indigo Medical US Inc., in Boston.

Read full description

The founder and CTO, Danaë Delbeke, has a PhD in Applied Sciences from Ghent University and a background in both photonics engineering and economics. Her work in photonics and a desire to make a tangible impact on quality of life led to the creation of Indigo. Delbeke is a serial entrepreneur, having founded or co-founded seven high-tech photonics companies. The management team includes CEO Peter J. Devlin, who has extensive experience at companies like Abbott Laboratories and Insulet Corporation.

The company's core product is a subcutaneously implanted CMM sensor designed to be invisible after insertion. This sensor utilizes proprietary nanophotonics technology, effectively a miniaturized spectrometer-on-a-chip, to measure the absorption of light in interstitial fluid. This allows for the simultaneous, continuous, and real-time monitoring of multiple metabolites like glucose, ketones, and lactate without using enzymes or fluorophores. The data is transmitted wirelessly via Bluetooth to a mobile app, providing users and their caregivers with actionable insights to manage their condition. The implantable sensor is designed to have a lifespan of up to two years.

Indigo's business model centers on the development and eventual commercialization of this medical device for the chronic disease management market. The company has raised significant capital to fund its research, development, and clinical trials. In 2016, it secured a €7 million Series A round. This was followed by a €38 million Series B round in 2020, led by Fund+, to prepare for and initiate clinical studies in Europe and the US. The company has successfully completed its first-in-human (GLOW) and longer-term stability (SHINE) clinical trials and has received ISO 13485:2016 certification for its quality management system. While the initial market is diabetes management, Indigo plans to explore applications for its CMM sensor in other chronic conditions such as kidney disease, oncology, and cardiovascular disease. Keywords: continuous metabolite monitoring, implantable sensor, nanophotonics, diabetes management, medical devices, glucose monitoring, ketone monitoring, silicon photonics, medtech, chronic disease

Source: Dealroom company data

At a glance

Status
Operational
Founded
2016
Headquarters
Ghent, Belgium
Employees
34
Open positions
1
Dealroom signal
74.6/100
Industry
Health
Sub-industry
Medical Devices
Sector
Health Tech & Medtech, Personal Health, Diabetes, Remote Monitoring, Spinout
Technology
Artificial Intelligence, Deep Tech, Machine Learning, Deep Learning, Computer Vision, IoT InternetOfThings
Business model
Manufacturing
Client focus
b2c

Latest news

Press, funding announcements and product moves mentioning Indigo Diabetes.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BEquity / VC Jul 2020 $42M $167M Ackermans & van Haaren · imec.xpand · FundPlus · Capricorn Partners
GRANTOther financing Feb 2018 $0 European Innovation Council
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearEBITDAMarginProfitMargin
2026
2025
2024
2023
2022
2021
2020
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Indigo Diabetes website traffic

Latest recorded traffic for Indigo Diabetes is 750 monthly website visits, down 5.1% over the last three months. Indigo Diabetes's team declined 2.9% over the past year.

Latest monthly visits750 3-month web change-5.1% 1-year team growth-2.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • European Innovation Council

Series A9 investors entered at this stage

  • PMV
  • Thuja Capital
  • Fidimec
  • Capricorn Partners
  • SoFi
  • Qbic Fund
  • FundPlus
  • Ackermans & van Haaren
  • imec.xpand

Other known investors3 additional known investors

  • Ghent University
  • imec
  • Quest for Growth
Team profiled 14 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇧🇪 Belgium75%
🇨🇦 Canada6.3%
🇮🇪 Ireland6.3%
🇳🇱 Netherlands6.3%
🇫🇷 France6.3%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Indigo Diabetes on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Indigo Diabetes’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.